Clinical Trials

Trial Name Description
IMvoke HN Dr. E. Winquist
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the
NRG HN001 Dr. Sara Kuruvilla
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Window of Opportunity Dr. Anthony Nichols
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment with BYL719.
ORATOR 2 HN Dr. D. Palma
A Phase II Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery
HN.9 Dr. Eric Winquist
"not yet open" Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Posi
RTOG1008 Dr. Varagur Venkatesan
A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High Risk Malignant Salivary Gland Tumors.
PDX Dr. Anthony Nichols
TumorGraft Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer - A Feasibility Study.
Keynote 412 HN Dr. E. Winquist
A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma

This information is updated by the Clinical Research Unit

LHSCResearch & Training

Last Updated August 3, 2007 | © 2007, LHSC, London Ontario Canada